Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for retinal angiomatous proliferation secondary to neovascular AMD
2014-002168-34Phase 4Completed
- Sponsor
- Eye Clinic of University Hospital Brno
- Start
- Sep 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of aflibercept in retinal angiomatous proliferation (RAP) and age-related macular degeneration (AMD), sponsored by Eye Clinic of University Hospital Brno. Primary endpoint: Change in best corrected visual acuity at 12 months. Started Sep 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
retinal angiomatous proliferation (RAP)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2014-002168-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002168-34.